|Download our latest brochure|
|Prescription Monitoring Program|
Hours: Mon-Fri 8:15 to 5:00
Virginia Prescription Monitoring Program
Virginia’s Prescription Monitoring Program (PMP) is a 24/7 database containing information on dispensed Schedule II-IV prescriptions and drugs of concern. The primary purpose of the PMP is to promote safe prescribing and dispensing practices for covered substances by providing timely and essential information to healthcare providers. Law enforcement and health profession licensing boards use the PMP to support investigations related to doctor shopping, diversion, and inappropriate prescribing and dispensing.
New CDC Guidelines
The Virginia PMP's third quarter report highlights new CDC guidance that impact morphine equivalent daily dose for prescribing practitioners. Read theQ3 report now.
Virginia's PMP Is Now Interoperable with North Carolina
On January 24 2018, Governor Ralph Northam announced that North Carolina is the most recent state to become interoperable with Virginia's PMP, an addition that makes Virginia's program fully integrated with more than half of U.S. states. Read the Governor's news release.
UVA Health System to Integrate Electronic Medical Record System with Prescription Monitoring Program (PMP)In order to improve patient safety in the battle against prescription drug and opioid abuse, the University of Virginia Health System in Charlottesville this month becomes the first large medical system in Virginia under a public-private grant to initiate use of the NarxCare Appriss digital bridge. NarxCare is used by prescribers and pharmacists within their work flow to expedite access to the Commonwealth’s Prescription Monitoring Program (PMP). Read the full press release.
Grant funding is available for integration of prescription information into electronic medical records and pharmacy software systems. Read the Governor’s news release.
Click on the image below to request more information.
Learn more about the public-private partnership working to integrate the Virginia PMP and NarxCare into your clinical workflow.
Virginia’s First Healthcare System Opts into Appriss Health’s NarxCare Platform
In the fight against prescription drug abuse and opioid addiction, prescribers at Tidewater’s Bayview Physicians Group and their patients are among the first beneficiaries of NarxCare by Appriss Health offered by Virginia’s Prescription Monitoring Program (PMP). Read the full press release.
Download the Virginia Data Submission Dispenser Guide for more details about the current submission requirements effective beginning July 1, 2018.
VIRGINIA PMP Technology Upgrade Information
- Your existing Virginia PMP account has automatically been transferred into the new software system.
- The old website, www.pmp.dhp.virginia.gov/VAPMPWebCenter, is no longer available.
- Your new username will be the email address where you received this notice.
How to Access the Virginia PMP:
- Navigate to: https://virginia.pmpaware.net.
- Click the ‘Reset Password’ button on the homepage.
- Instructions will be emailed to you for resetting your password.
- If the email does not appear in your inbox, please check the spam folder.
- Once you have reset your password, you will be logged into the system.
- If prompted, update demographic information.
- To request patient reports, please review the How to Make a Request Guide.
Users may want to review the User Support Manual for in depth details.
For Technical Assistance: Contact Appriss at 1-855-4VA-4PMP (1-855-482-4767) Or submit a support request at: https://apprisspmp.zendesk.com/hc/en-us/requests/new
Should you have any questions regarding this transition, you may contact the Virginia Prescription Monitoring Program at (804) 367-4514 or (804) 367-4409 or by email at firstname.lastname@example.org.
Opioid Addiction Crisis Declared a Public Health Emergency in Virginia
On November 21, 2016 Governor McAuliffe issued a News Release stating that State Health Commissioner Marissa Levine has declared Virginia’s opioid abuse crisis a Public Health Emergency in the Commonwealth.
FDA News Release
The FDA announced on August 31, 2016 that strong warnings are issued against the concurrent use of prescription opioid analgesics and cough medicines along with benzodiazepines. Serious risks and death have been associated with this combination. For more information please read the annoucement